The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction

The significant morbidity and mortality associated with heart failure with reduced (HFrEF) or preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. The nitric oxide (NO)–soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays an important ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Aimo, Alberto, Castiglione, Vincenzo, Vergaro, Giuseppe, Panichella, Giorgia, Senni, Michele, Lombardi, Carlo Mario, Emdin, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197896/
https://www.ncbi.nlm.nih.gov/pubmed/34291399
http://dx.doi.org/10.1007/s10741-021-10146-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197896/
https://www.ncbi.nlm.nih.gov/pubmed/34291399
http://dx.doi.org/10.1007/s10741-021-10146-1

Ejemplares similares